Cravings, emotional eating patterns, and reward-driven food behaviors gradually diminish
Eli Lilly's May 21, 2026 announcement reported mean body-weight reduction of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg, compared with 2.2% on placebo [1][2]
The evidence supporting this view: Patients who develop heartburn on GLP-1 medications and manage it with behavioral changes alone lose more weight than patients who immediately start PPIs (retrospective analysis, Kochar et al., Obesity 2024)
Taken together, these points underscore FDAs view that compounded GLP1 products present concrete patient-safety and supplychain risks that warrant heightened scrutiny
we are seeing an explosion of hype, repackaging older studies